GlassScriptPhysician profile
Laura Troidle
NPI 1548256282
$6,991.53
in general payments reported to CMS, 2019-2025
28 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $1,413 · 2023: $1,234 · 2024: $1,636 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,957 · Education: $25.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,957.43 |
| Education | $25.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $884.23 | 2021-2025 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $815.66 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $527.39 | 2022-2025 | Filspari |
| Novo Nordisk INC | $526.69 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $459.19 | 2022-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $381.66 | 2021-2025 | Jynarque |
| Akebia Therapeutics INC | $381.29 | 2022-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.01 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $326.43 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $272.08 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $258.34 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $238.16 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $235.07 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Glaxosmithkline, LLC. | $220.30 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $183.05 | 2022-2024 | Veltassa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $172.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $125.96 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $123.77 | 2021-2024 | Ultomiris |
| Lilly USA, LLC | $91.61 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $91.01 | 2021-2025 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $78.20 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $65.95 | 2024-2025 | Givlaari |
| Horizon Therapeutics Plc | $52.01 | 2022-2023 | Krystexxa |
| Kyowa Kirin, INC. | $38.24 | 2023-2024 | Crysvita |
| Apellis Pharmaceuticals, INC. | $33.04 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $21.55 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.98 | 2024 | |
| Cormedix INC. | $18.41 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Troidle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.